Clinical trials: Mutation Burden
Recurrent Cervical Cancer, Nucleotide Variant
Genetic Mutation in Recurrent Cervical Cancer
Little is known about the characteristics of genetic mutation in recurrent cervical cancer. This study is to explore the targeted genetic mutations via a multi-gene panel, which consists of more than 500 hundred genes.
- Conditions
- Recurrent Cervical Cancer, Nucleotide Variant, Copy Number Variation, Insertion-deletion Variation
- Trial name
- NCT04191226
- Testing
- Multi-gene panel testing
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Lei Li
Resectable Pancreatic Ductal Adenocarcinoma
Nalirinox Neo-pancreas RAS Mut ctDNA Study
Pancreatic cancer has an unfavorable prognosis with a reduced possibility of long-term survival. The only treatment with curative potential is surgery, but it is only possible in 15-20% of cases.
- Trial name
- NCT04010552
- Testing
- NALRINOX combination
- Where
- 3 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Fundación de investigación HM
Colorectal Cancer
PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer
PD-1(programmed death protein 1)antibody has been to approved in patients with MSI-H/dMMR advanced cancer and has achieved significant efficacy.
- Trial name
- PCOX (NCT03638297)
- Testing
- PD-1 antibody + cox inhibitor
- Where
- 2 sites in China
- Volunteers
- 29 people
- Sponsor
- Sun Yat-sen University
Bladder Cancer, Melanoma
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
The purpose of this study is to investigate the characteristics of tumors in patients treated with nivolumab and to identify features that help to predict a good or bad response to this drug.
- Trial name
- NCT02553642
- Testing
- Nivolumab, Nivolumab plus Ipilimumab
- Where
- 5 sites in United States
- Volunteers
- 81 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chemotherapy Effect, Immunotherapy
Effect of Chemotherapy on TMB in NSCLC
Tumor mutation burden is identified as an important biomarkers for predicting PD-1/PD-L1 inhibitors in advanced Non-Small Cell Lung Cancer.
- Conditions
- Chemotherapy Effect, Immunotherapy, Tumor Mutation Burden, PD-1/L1 Inhibitor
- Trial name
- NCT03683407
- Testing
- Next-Genernation Sequence
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Baodong Qin
Non-Small Cell Lung Cancer
Multicenter Observational Study of Advanced Non-small Cell Lung Cancer With Malignant Pleural Effusion
Multicenter observational study for correlation between tumor mutation burden and immunotherapy efficacy of advanced non-small cell lung cancer with malignant pleural effusion
- Trial name
- NCT04263688
- Testing
- Non-Intervention
- Volunteers
- 300 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Chronic Myeloid Leukemia
French Study to Highlight the Unmet Treatment Needs of 3L+ CP-CML and With T315I-mutated CML Patients
A retrospective multi-center cohort study design was used to address the study objectives, using medical records obtained from three clinical centers in France.
- Trial name
- NCT05619978
- Testing
- 3L Therapy, T315I
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Atherosclerosis
Arterial Function and Atherosclerosis in Essential Thrombocythemia
The aim of the study is to examine (a) whether patients with JAK2 V617F positive ET in comparison to age-and sex-matched, apparently healthy control subjects show more advanced progression of arterial stiffness, pulse-wave…
- Trial name
- NCT03828422
- Testing
- imaging
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- University Medical Centre Ljubljana
Malignant Hydrothorax, NSCLC
A Prospective Study to Evaluate the Consistency of Next-Generation Sequencing(NGS)-Panels by Using Malignant Hydrothorax Form NSCLC
A prospective study to evaluate consistency of different NGS-panel. Cell free DNA is purified from each malignant hydrothorax from NSCLC .Different NGS-panels are applied to perform in vitro diagnosis to detect Single Nucleotide…
- Trial name
- NCT03546452
- Testing
- in vitro NGS-panel
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
Pancreatic Cancer
Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer
A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with high tumour mutation burden
- Trial name
- NCT05093231
- Testing
- Pembrolizumab, Olaparib
- Where
- 17 sites in Australia, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Myeloproliferative Neoplasm, Essential Thrombocythemia
Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)
Prospective study to evaluate the relevance of CALR allele burden monitoring as a molecular marker of disease progression.
- Conditions
- Myeloproliferative Neoplasm, Essential Thrombocythemia, Primary Myelofibrosis, Prefibrotic Stage, Primary Myelofibrosis, Fibrotic Stage
- Trial name
- CALRSUIVI (NCT04942080)
- Testing
- CALR allele burden quantification
- Where
- 10 sites in France
- Volunteers
- 260 people
- Sponsor
- University Hospital, Angers
Mitochondrial Myopathies
mtDNA Mutation Load Analysis in Mesoangioblasts
Mitochondrial diseases caused by defects in oxidative phosphorylation (OXPHOS) due to heteroplasmic mitochondrial DNA (mtDNA) mutations are rare (frequency 1/5,000), but severe multi-system disorders.
- Trial name
- MABS05 (NCT05199740)
- Testing
- in vitro analysis
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Maastricht University
Colorectal Cancer
Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients
This is a prospective, Single arm Phase II trial. Patients were eligible to participate when they had histological or cytological confirmed metastatic colorectal adenocarcinoma Non-MSI(microsatellite instability)-high and…
- Trial name
- NCT04695470
- Testing
- Fruquintinib and Sintilimab
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Aiping Zhou
Myeloproliferative Neoplasm, Primary Myelofibrosis
Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation
The aim of this phase II study is to test a novel concept in the treatment of patients with myeloproliferative neoplasms (MPN), a disease of the bone marrow.
- Conditions
- Myeloproliferative Neoplasm, Primary Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera
- Trial name
- NCT02311569
- Testing
- Mirabegron
- Where
- 11 sites in Switzerland
- Volunteers
- 39 people
- Sponsor
- Swiss Cancer Institute